Pelvic Congestion Syndrome Treatment Market
Pelvic Congestion Syndrome Treatment Market Study by Primary Pelvic Congestion Syndrome Treatment and Secondary Pelvic Congestion Syndrome Treatment From 2024 to 2034
Analysis of Pelvic Congestion Syndrome Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Pelvic Congestion Syndrome Treatment Market Outlook (2024 to 2034)
Worldwide revenue from the demand for pelvic congestion syndrome treatment market is estimated to stand at US$ 1.44 billion in 2024. The market is evaluated to advance at a 9.9% CAGR to reach US$ 3.7 billion by 2034.
Increased funding for research, diagnostic tools, and pelvic congestion syndrome (PCS) treatment choices is a result of growing healthcare expenditures. Through early diagnosis and cutting-edge therapies, such as minimally invasive procedures, including pelvic vein embolization, healthcare practitioners enhance patient outcomes thanks to this financial support.
In addition, increased healthcare spending makes it easier to build specialized medical facilities and train medical staff to manage PCS. In the end, more spending improves access to all-encompassing treatment, increases patient and healthcare provider knowledge, and spurs innovation in PCS management techniques, all of which support the PCS market's overall expansion.
More individuals are correctly identified with PCS as awareness grows, which raises the need for management alternatives and therapies. Improved knowledge of PCS symptoms, such as persistent pelvic pain and discomfort, as well as related issues, including dyspareunia (painful sex) and decreased quality of life, is what is driving this awareness.
PCS is included in differential diagnosis by medical professionals more frequently, which is leading to early referrals for specialist care and therapeutic interventions, including minimally invasive treatments, such as pelvic vein embolization. In the end, improved PCS detection encourages the development of medical services and treatment approaches that are customized to the requirements of impacted patients, propelling market expansion in this niche of gynecological and interventional radiology practices.
Access to specialist treatment and diagnostic facilities is improved by the development of healthcare infrastructure. This includes the creation and growth of pain management facilities, interventional radiology departments, and gynecological clinics that are capable of accurately diagnosing and treating PCS.
Advanced imaging modalities, such as pelvic venography and ultrasound are adopted owing to improved infrastructure, which makes it easier to diagnose and track PCS. Furthermore, the delivery of minimally invasive operations, such as pelvic vein embolization-which needs specialized equipment and qualified medical personnel-is supported by infrastructure development.
| Report Attribute | Detail |
|---|---|
| Pelvic Congestion Syndrome Treatment Market Size (2024E) | US$ 1.44 Billion |
| Forecasted Market Value (2034F) | US$ 3.7 Billion |
| Global Market Growth Rate (2024 to 2034) | 9.9% CAGR |
| North America Market Value (2024E) | US$ 511.75 Million |
| Canada Market Value (2034F) | US$ 166.6 Million |
| Hospitals Segment Growth Rate (2024 to 2034) | 10.5% CAGR |
| United States Market Value (2034F) | US$ 1.32 Billion |
| Key Companies Profiled | Sanofi; TOLMAR Inc.; Actiza Pharmaceuticals; Pfizer; Debio RP; AbbVie Inc.; AstraZeneca; Novartis Pharmaceuticals Corporation; Indivior Inc.; Pernix Ireland Pain Limited; ALZA Corporation; Fresenius Kabi USA, LLC |
Pelvic congestion syndrome is a condition that causes pain in the pelvic region. This pain occurs mostly due to problems in the veins near the pelvic area. Pelvic congestion syndrome is a common gynecological condition in women that leads to often severe chronic pelvic pain.
The causes of pelvic congestion syndrome generally involve pelvic inflammatory disease, endometriosis, pelvic varicosities, and other conditions. Mostly in hospitals, pelvic congestion syndrome diagnosis is generally performed by venography. Before a venogram, a pelvic ultrasound or other imaging study is performed to check for any abnormalities.
According to a study reported in 2016, it is estimated that 10 million women suffer from pelvic congestion syndrome with approximately 7 million women avoiding seeking treatment. Worldwide prevalence of chronic pelvic pain is estimated to vary from 26.6% in Egypt and 5.7% in Austria. The economic scenario of the pelvic congestion syndrome has a great impact.
The annual medical cost of pelvic congestion syndrome diagnosis and pelvic congestion syndrome treatment is estimated to be around US$ 1.2 billion and the cost of lost productivity in patients with pelvic congestion syndrome treatment is estimated to be around US$ 15 billion annually.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Pelvic Congestion Syndrome Treatment: Market Dynamics
Pelvic congestion syndrome is a common issue among women between 20 and 50 years of age. Mostly doctors prescribed painkillers for pelvic congestion syndrome treatment to reduce the pain. Apart from this hormonal therapy is also given to reduce the congestion in pelvic congestion syndrome treatment.
Various treatment procedures for pelvic congestion syndrome treatment expected to drive the market. Hormonal treatment helps to reduce congestion and blood flow of the viscous vein.
If this pelvic congestion syndrome treatment fails, minimally invasive therapies, such as nonsurgical embolization are mostly used in pelvic congestion syndrome treatment. Advancement in latest technologies and procedures is boosting the pelvic congestion syndrome treatment market.
The lack of skilled professionals and lack of awareness among people restrain the growth of the pelvic congestion syndrome treatment market. The cost of embolization procedures is also another factor that hinders the pelvic congestion syndrome treatment market.
Pelvic Congestion Syndrome Treatment Market: Overview
The pelvic congestion syndrome treatment market is expected to have gradual growth. Medical pelvic congestion syndrome treatment includes danazol, psychotherapy, progestin, phlebotonics, gonadotropins receptor agonists (GnRH) which is done by hormone replacement therapy, nonsteroidal anti-inflammatory drugs, and dihydroergotamine.
In addition, some of the latest technologies, which consist of transcatheter embolotherapy, are currently used in pelvic congestion syndrome treatment. Medical therapy has shown to provide relief to the patients but the outcome is for a shorter period.
However, a Gonadotrophin-releasing hormone agonist called goserelin has shown satisfactory results in pelvic congestion syndrome treatment pain. Apart from this, hysterectomy with oophorectomy has proven to provide moderate relief to patients with pelvic congestion syndrome treatment. Embolotherapy has been an exciting therapy in pelvic congestion syndrome treatment.
With advances in medical sciences, the pelvic congestion syndrome treatment market is expected to have significant growth in the next few years.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Pelvic Congestion Syndrome Treatment Market: Region-wise Outlook
Based on geography, the global pelvic congestion syndrome treatment market is segmented into seven key regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan, Japan, and the Middle East & Africa.
North America is expected to dominate the global pelvic congestion syndrome treatment market due to advancements in technology, high healthcare facilities, and improved infrastructure, which will facilitate the growth of the pelvic congestion syndrome treatment market.
Europe is also contributing to market growth owing to the adoption of new treatment options and availability of drugs and an increase in procedures of injectables used for pelvic congestion syndrome treatment.
Asia Pacific is expected to have the potential to drive the global pelvic congestion syndrome treatment market due to the increase in the prevalence of pelvic congestion syndrome. According to one report, the prevalence rate of chronic pelvic pain in developing countries accounts for 5.2% in India and 43.2% in Thailand. Among these cases, pelvic congestion syndrome reports 16% to 31% of all cases, which is having a considerable growth in the pelvic congestion syndrome treatment market.
Middle East and Africa have less potential to drive the market due to a lack of awareness among people and poor healthcare facilities restrain the growth of the pelvic congestion syndrome treatment market.
Pelvic Congestion Syndrome Treatment Market: Key Players
Some of the key players present across the value chain of the global pelvic congestion syndrome treatment market are Sanofi, TOLMAR Inc., Actiza Pharmaceuticals, Pfizer, Debio RP, AbbVie Inc., AstraZeneca, Novartis Pharmaceuticals Corporation, Indivior Inc., Pernix Ireland Pain Limited, ALZA Corporation, Fresenius Kabi USA, LLC.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
The report covers an exhaustive analysis on :
- Market Segments
- Market Dynamics
- Market Size
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Value Chain
The regional analysis includes :
- North America (United States, Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, United Kingdom, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia-Pacific Excluding Japan (China, India, ASEAN, Australia & New Zealand)
- Japan
- The Middle East and Africa (GCC, S. Africa, N. Africa)
The report is a compilation of first-hand information, qualitative and quantitative assessments by industry analysts, and inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macroeconomic indicators, and governing factors along with market attractiveness as per segments.
The report also maps the qualitative impact of various market factors on market segments and geograp
Report Highlights :
- Detailed overview of the parent market
- Changing market dynamics in the industry
- In-depth market segmentation
- Historical, current, and projected market size in terms of volume and value
- Recent industry trends and developments
- Competitive landscape
- Strategies of key players and products offered
- Potential and niche segments, geographical regions exhibiting promising growth
- A neutral perspective on market performance
Segmentations of the Pelvic Congestion Syndrome Treatment Market Research
-
By Disease Type :
- Primary Pelvic Congestion Syndrome Treatment
- Secondary Pelvic Congestion Syndrome Treatment
-
By Medication :
- NSAIDs
- Psycotherapy Pelvic Congestion Syndrome Treatment
- Analgesics Pelvic Congestion Syndrome Treatment
- Dihydrogotamine
- Progestins
- Others
-
By Distribution Channel :
- Hospitals
- Diagnostic Laboratories
- Gynecology Clinics
- Ambulatory Surgical Centers
-
By Region :
- North America
- Western Europe
- Eastern Europe
- Latin America
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis and Forecast
- 6.1. Disease Type
- 6.2. Medication
- 6.3. Distributional Channel
- 7. Global Market Analysis and Forecast, By Disease Type
- 7.1. Primary
- 7.2. Secondary
- 8. Global Market Analysis and Forecast, By Medication
- 8.1. NSAIDs (nonsteroidal anti-inflammatory drugs)
- 8.2. Psychotherapy
- 8.3. Analgesics
- 8.4. Dihydroergotamine
- 8.5. Progestins
- 8.6. Others
- 9. Global Market Analysis and Forecast, By Distributional Channel
- 9.1. Hospital
- 9.2. Diagnostics Laboratories
- 9.3. Gynecology Clinics
- 9.4. Ambulatory Surgical Centers
- 10. Global Market Analysis and Forecast, By Region
- 10.1. North America
- 10.2. Latin America
- 10.3. Western Europe
- 10.4. Eastern Europe
- 10.5. Asia Pacific
- 10.6. East Asia
- 10.7. MEA
- 11. North America Sales Analysis and Forecast, by Key Segments and Countries
- 12. Latin America Sales Analysis and Forecast, by Key Segments and Countries
- 13. Western Europe Sales Analysis and Forecast, by Key Segments and Countries
- 14. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries
- 15. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries
- 16. East Asia Sales Analysis and Forecast, by Key Segments and Countries
- 17. MEA Sales Analysis and Forecast, by Key Segments and Countries
- 18. Sales Forecast by Disease Type, Medication, and Distributional Channel for 30 Countries
- 19. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 20. Company Profile
- 20.1. Sanofi
- 20.2. TOLMAR Inc.
- 20.3. Actiza Pharmaceuticals
- 20.4. Pfizer
- 20.5. Debio RP
- 20.6. AbbVie Inc.
- 20.7. AstraZeneca
- 20.8. Novartis Pharmaceuticals Corporation
- 20.9. Indivior Inc.
- 20.10. Pernix Ireland Pain Limited
- 20.11. ALZA Corporation
- 20.12. Fresenius Kabi USA, LLC
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Disease Type
Table 3: Global Market US$ Mn Forecast by Medication
Table 4: Global Market US$ Mn Forecast by Distributional Channel
Table 5: North America Market US$ Mn Forecast by Country
Table 6: North America Market US$ Mn Forecast by Disease Type
Table 7: North America Market US$ Mn Forecast by Medication
Table 8: North America Market US$ Mn Forecast by Distributional Channel
Table 9: Latin America Market US$ Mn Forecast by Country
Table 10: Latin America Market US$ Mn Forecast by Disease Type
Table 11: Latin America Market US$ Mn Forecast by Medication
Table 12: Latin America Market US$ Mn Forecast by Distributional Channel
Table 13: Western Europe Market US$ Mn Forecast by Country
Table 14: Western Europe Market US$ Mn Forecast by Disease Type
Table 15: Western Europe Market US$ Mn Forecast by Medication
Table 16: Western Europe Market US$ Mn Forecast by Distributional Channel
Table 17: Eastern Europe Market US$ Mn Forecast by Country
Table 18: Eastern Europe Market US$ Mn Forecast by Disease Type
Table 19: Eastern Europe Market US$ Mn Forecast by Medication
Table 20: Eastern Europe Market US$ Mn Forecast by Distributional Channel
Table 21: Asia Pacific Market US$ Mn Forecast by Country
Table 22: Asia Pacific Market US$ Mn Forecast by Disease Type
Table 23: Asia Pacific Market US$ Mn Forecast by Medication
Table 24: Asia Pacific Market US$ Mn Forecast by Distributional Channel
Table 25: East Asia Market US$ Mn Forecast by Country
Table 26: East Asia Market US$ Mn Forecast by Disease Type
Table 27: East Asia Market US$ Mn Forecast by Medication
Table 28: East Asia Market US$ Mn Forecast by Distributional Channel
Table 29: MEA Market US$ Mn Forecast by Country
Table 30: MEA Market US$ Mn Forecast by Disease Type
Table 31: MEA Market US$ Mn Forecast by Medication
Table 32: MEA Market US$ Mn Forecast by Distributional Channel
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 4: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 5: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 7: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 8: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 9: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 10: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 13: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 14: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 15: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 17: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 18: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 19: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 20: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 22: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 23: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 24: Asia Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 25: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 26: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 27: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 28: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 29: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Disease Type
Figure 30: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Medication
Figure 31: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Distributional Channel
Figure 32: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the market valuation for pelvic congestion syndrome in 2024?
The pelvic congestion syndrome market is valued at US$ 1.44 billion in 2024.
What is the forecasted CAGR from 2024 to 2034?
The market is forecasted to expand at a CAGR of 9.9% between 2024 and 2034.
Pelvic Congestion Syndrome Treatment Market